Outcomes following single-treatment Gamma Knife surgery for trigeminal neuralgia with a minimum 3-year follow-up
Clinical article
Search for other papers by Ron I. Riesenburger in
Current site
Google Scholar
PubMed
Search for other papers by Steven W. Hwang in
Current site
Google Scholar
PubMed
Search for other papers by Clemens M. Schirmer in
Current site
Google Scholar
PubMed
Search for other papers by Vasilios Zerris in
Current site
Google Scholar
PubMed
Search for other papers by Julian K. Wu in
Current site
Google Scholar
PubMed
Search for other papers by Kerry Mahn in
Current site
Google Scholar
PubMed
Search for other papers by Paul Klimo Jr. in
Current site
Google Scholar
PubMed
Search for other papers by John Mignano in
Current site
Google Scholar
PubMed
Search for other papers by Clinton J. Thompson in
Current site
Google Scholar
PubMed
Search for other papers by Kevin C. Yao in
Current site
Google Scholar
PubMed
Object
Gamma Knife surgery (GKS) has been shown to be effective in treating trigeminal neuralgia (TN). Existing studies have demonstrated success rates of 69.1–85% with median follow-up intervals of 19–60 months. However, series with uniform long-term follow-up data for all patients have been lacking. In the present study the authors examined outcomes in a series of patients with TN who underwent a single GKS treatment followed by a minimum follow-up of 36 months. They used a clinical scale that simplifies the reporting of outcome data for patients with TN.
Methods
Fifty-three consecutive patients with typical, intractable TN received a median maximum radiation dose of 80 Gy applied with a single 4-mm isocenter to the affected trigeminal nerve. Follow-up data were obtained by clinical examination and questionnaire. Outcome results were categorized into the following classes (in order of decreasing success): Class 1A, complete pain relief without medications; 1B, complete pain relief with either a decrease or no change in medications; 1C, ≥ 50% pain relief without medications; 1D, ≥ 50% pain relief with either a decrease or no change in medications; and Class 2, < 50% pain relief and/or increase in medications. Patients with Class 1A–1D outcome (equivalent to Barrow Neurological Institute Grades I–IIIb) were considered to have a good treatment outcome, whereas in patients with Class 2 outcome (equivalent to Barrow Neurological Institute Grades IV and V) treatment was considered to have failed.
Results
A good treatment outcome from initial GKS was achieved in 31 (58.5%) patients for whom the mean follow-up period was 48 months (range 36–66 months). Outcomes at last follow-up were reflected by class status: Class 1A, 32.1% of patients; 1B, 1.9%; 1C, 3.8%; 1D, 20.8%; and Class 2, 41.5%. Statistical analysis showed no difference in outcomes between patients previously treated with microvascular decompression or rhizotomy compared with patients with no previous surgical treatments. Thirty-six percent of patients reported some degree of posttreatment facial numbness. Anesthesia dolorosa did not develop in any patient.
Conclusions
Despite a time-dependent deterioration in the success rate of GKS for medically intractable TN, the authors' study showed that > 50% of patients can be expected to have a good outcome based on their scoring system, with ~ 33% having an ideal outcome (pain free with no need for medications). Long-term data, as those presented here, are important when counseling patients on their treatment options.
Abbreviations used in this paper:
BNI = Barrow Neurological Institute; GKS = Gamma Knife surgery; MS = multiple sclerosis; MVD = microvascular decompression; TN = trigeminal neuralgia.
© Copyright 1944-2023 American Association of Neurological Surgeons